ELC Group has announced that it has been awarded a 1.5 million Euro contract by one of China’s biggest pharmaceutical companies.
The contract award is a major endorsement of ELC Group’s new Concept to Commercialization solution approach, which delivers a highly integrated portfolio of regulatory affairs consultancy services to customers, from the development stage through to the implementation of clinical trials, completion of product registration, and successful marketing of the product.
The major project, which will see two products taken through ELC Group’s end-to-end Concept to Commercialization service, is expected to be complete by the end of 2016. The customer, one of the top 25 Chinese pharmaceutical companies, is an active pharmaceutical ingredient company that is moving towards the finished formulation business.
ELC Group was successfully selected for the contract following a rigorous qualification process, which compared ELC Group against a number of other domestic and international Clinical Research Organizations (CROs). The key measurement criteria included experience, quality of work, timeline, costing and working culture.
The client was impressed by ELC Group’s comprehensive Concept to Commercialization model and confident that ELC Group could be relied on to support their crucial international market expansion plan. Additionally, open communication, common language and cultural understanding were key factors that helped ELC to stand out in the tendering process as the ultimate partner.
Commenting on the landmark deal, ELC Group CEO Marco Rubinstein said: “Breaking boundaries is becoming a norm for ELC Group, and this landmark contract award marks an exciting new level for us, both in size and scope of projects.” He added: “This latest deal really validates our Concept to Commercialization partnership approach and its strengths in delivering end-to-end support to customers targeting ambitious growth.”